Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,123,951
  • Shares Outstanding, K 147,694
  • Annual Sales, $ 69,720 K
  • Annual Income, $ -562,540 K
  • 60-Month Beta 1.20
  • Price/Sales 15.66
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BBIO with:

Options Overview Details

View History
  • Implied Volatility 103.09% ( -6.24%)
  • Historical Volatility 118.99%
  • IV Percentile 75%
  • IV Rank 29.20%
  • IV High 240.61% on 12/20/21
  • IV Low 46.37% on 06/16/21
  • Put/Call Vol Ratio 0.11
  • Today's Volume 473
  • Volume Avg (30-Day) 466
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 16,868
  • Open Int (30-Day) 30,432

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.03
  • Number of Estimates 5
  • High Estimate -0.92
  • Low Estimate -1.12
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -56.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.98 +47.39%
on 05/12/22
10.34 -29.01%
on 04/25/22
-2.68 (-26.75%)
since 04/22/22
3-Month
4.98 +47.39%
on 05/12/22
12.47 -41.14%
on 04/05/22
unch (unch)
since 02/23/22
52-Week
4.98 +47.39%
on 05/12/22
21.78 -66.29%
on 07/07/21
-11.96 (-61.97%)
since 05/21/21

Most Recent Stories

More News
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

- PTR-01 was well-tolerated over a four-month treatment period in RDEB patients - Treatment with PTR-01 led to rapid, consistent, and durable wound...

BBIO : 7.34 (-3.55%)
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates

Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.

BMY : 76.70 (+0.67%)
GILD : 63.66 (-0.28%)
CMRX : 2.35 (unch)
BBIO : 7.34 (-3.55%)
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor

BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.

BMY : 76.70 (+0.67%)
AMGN : 249.04 (+0.62%)
ALKS : 29.30 (-2.33%)
BBIO : 7.34 (-3.55%)
10 Amazing Stocks Under $10 (Part II)

Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.

ADPT : 7.90 (+2.46%)
MSFT : 260.65 (+3.20%)
HIMX : 9.39 (+0.11%)
FUBO : 3.23 (+1.89%)
BBIO : 7.34 (-3.55%)
DNA : 2.68 (+2.68%)
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years

-Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million ...

BBIO : 7.34 (-3.55%)
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments...

BBIO : 7.34 (-3.55%)
BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference

PALO ALTO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

BBIO : 7.34 (-3.55%)
BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BBIO : 7.34 (-3.55%)
BHC : 9.79 (-1.41%)
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update

–Completed sale to Sentynl Therapeutics of BridgeBio’s NULIBRY™ (Fosdenopterin) for Injection–Updated strategic collaboration with Helsinn Group to...

BBIO : 7.34 (-3.55%)
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of -10.53% and 2.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PSNL : 4.36 (-1.58%)
BBIO : 7.34 (-3.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 7.95
2nd Resistance Point 7.80
1st Resistance Point 7.57
Last Price 7.34
1st Support Level 7.18
2nd Support Level 7.03
3rd Support Level 6.80

See More

52-Week High 21.78
Fibonacci 61.8% 15.36
Fibonacci 50% 13.38
Fibonacci 38.2% 11.40
Last Price 7.34
52-Week Low 4.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar